The Pharmacology Center

Filter Your Results

 

News

 

FDA Approves Indication for Xarelto to Reduce Risk of Major CV Events in Patients With Chronic CAD or PAD

October 11, 2018 -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Xarelto (rivaroxaban) to reduce the risk of major cardiov…

OAC-ALONE Studies Antithrombotic Therapy Beyond 1-Year for Stent Patients With Atrial Fibrillation

September 24, 2018 -- The Cardiovascular Research Foundation (CRF) announced that findings from the first randomized trial of its kind was unable to establish noninferiority o…

Medtronic Begins 1-Month DAPT Clinical Study in the United States and Japan

September 13, 2018 -- Medtronic announced the start of the Onyx ONE Clear study in the United States and Japan. Onyx ONE Clear will evaluate 1-month dual antiplatelet the…

GLOBAL LEADERS Trial Presented at ESC Congress

August 27, 2018 -- The European Society of Cardiology (ESC) announced that findings from the GLOBAL LEADERS trial demonstrated that long-term antiplatelet monotherapy after st…

Study Evaluates Risks and Benefits of Prolonged DAPT After Stenting in Women

August 13, 2018 -- An analysis of the benefits and risks of prolonged dual antiplatelet therapy (DAPT) after coronary stenting in women was conducted by the DAPT study investi…

Medicure Launches Zypitamag Statin in the United States

May 15, 2018 -- Medicure Inc. recently announced that its Zypitamag (pitavastatin magnesium) tablets are now available in the United States, where they are sold through the co…

Elective Coronary Revascularization Procedures Evaluated in Patients With Stable CAD

May 14, 2018 -- Findings from a study describing the incidence, determinants, and outcomes of elective coronary revascularization (ECR) in patients with stable coronary artery…

FDA Approves Portola Pharmaceuticals’ Andexxa for the Reversal of Factor Xa

May 14, 2018 -- Portola Pharmaceuticals, Inc. recently announced that the US Food and Drug Administration (FDA) has approved the company's Andexxa (coagulation factor Xa […

 

advertisement

US Device Guide

The Cardiac Interventions Today Europe Device Guide offers a searchable, comprehensive listing of the available interventional cardiology devices in the United States.

 

Top 5 Top 5 In Pharmacology Center

FDA Seeks to Strengthen Public Warnings and Recall Notifications; CDRH Outlines Strategic Priorities

Abbott Vascular's XIENCE 28 GLOBAL Trial Enrolls First Patient in Europe

SMART-DATE Trial Shows Increased Risk of Heart Attack With Short-Term DAPT in ACS Patients

Alirocumab PCSK9 Inhibitor Studied in ODYSSEY Outcomes Trial of ACS Patients

Two-Year ADAPT-DES Data Examine Relationship of IVUS Guidance on DES Outcomes

 

Centers

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

Other Resources

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.